Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Revenue (2021 - 2024)

Historic Revenue for Allogene Therapeutics (ALLO) over the last 4 years, with Q1 2024 value amounting to $22000.0.

  • Allogene Therapeutics' Revenue fell 2666.67% to $22000.0 in Q1 2024 from the same period last year, while for Dec 2024 it was $22000.0, marking a year-over-year decrease of 7684.21%. This contributed to the annual value of $22000.0 for FY2024, which is 7684.21% down from last year.
  • Allogene Therapeutics' Revenue amounted to $22000.0 in Q1 2024, which was down 2666.67% from $21000.0 recorded in Q4 2023.
  • Allogene Therapeutics' Revenue's 5-year high stood at $75.7 million during Q4 2021, with a 5-year trough of $21000.0 in Q4 2023.
  • Moreover, its 4-year median value for Revenue was $30000.0 (2023), whereas its average is $8.8 million.
  • Within the past 5 years, the most significant YoY rise in Allogene Therapeutics' Revenue was 4545.45% (2022), while the steepest drop was 9996.56% (2022).
  • Allogene Therapeutics' Revenue (Quarter) stood at $75.7 million in 2021, then plummeted by 99.97% to $26000.0 in 2022, then decreased by 19.23% to $21000.0 in 2023, then increased by 4.76% to $22000.0 in 2024.
  • Its Revenue was $22000.0 in Q1 2024, compared to $21000.0 in Q4 2023 and $22000.0 in Q3 2023.